Ensoma reports that the Danish Business Authority has cleared its acquisition of Twelve Bio, according to Danish foreign direct investment laws. As a result, the Co-founder of Twelve Bio, Stefano Stella, has joined the leadership team at Ensoma as vice president of gene editing. Moreover, Guillermo Montoya, co-founder of Twelve Bio, and Shengdar Q. Tsai, a member of the scientific advisory board of Twelve Bio, will join the scientific advisory board at Ensoma.
The first patient has been dosed in the phase 1 trial of Century Therapeutics gene-edited therapeutic CNTY-101 for relapsed or refractory CD19 positive B-cell lymphomas. CNTY-101 is an allogeneic cell therapy product candidate with six genetic modifications incorporated using sequential rounds of CRISPR. The modifications include a CD19-CAR, Allo-Evasion™ technology, IL-15 cytokine support and a safety switch.
Advances in gene therapy hold promise for treating hereditary hearing loss. The review addresses three main gene therapy strategies - gene replacement, gene suppression, and gene editing, summarising which approach is most appropriate for particular monogenic diseases based on different pathogenic mechanisms and then focusing on their successful applications for HHL in preclinical trials. Finally, it elaborates on the challenges and outlooks of gene therapy for HHL.